Researchers evaluated a different chemo regimen in combination with Braftovi and Erbitux, which is already approved with mFOLFOX6.

Distance, lack of coverage, and mistrust have limited Indigenous patients' access to basic and advanced medicine, but cancer centers are embracing strategies to change that.

The agency last December approved subcutaneous Rybrevant on a biweekly dosing schedule across all of its indications.

The company acquired GH31 from Chinese firm Genhouse for $80 million up front and will test it in tumors with MTAP deletions.

The firm originally submitted a new drug application seeking approval of the drug in 2016, which was rejected, and, in 2024, resubmitted an application.